Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDF, FTC, and AZT in Antiretroviral Naive HIV-1 Patients
NCT00199121Phase 4Unknown
- Sponsor
- Universitätsklinikum Frankfurt
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tenofovir disoproxil fumarate, emtricitabine and zidovudine in human immunodeficiency virus infection (HIV), sponsored by Universitätsklinikum Frankfurt. Primary endpoints: Antiviral response (HIV-1 RNA PCR) at 48 weeks and Safety and tolerability at 48 weeks. Status: unknown.
02
Drugs
tenofovir disoproxil fumarateemtricitabinezidovudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00199121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00199121.